Alan S. Wayne, MD

Chair, Department of Pediatrics

Professor of Pediatrics, Medicine, and Cancer Biology, Keck School of Medicine of USC

Pediatrician-in-Chief and Senior Vice President of Academic Affairs

Pasadena Guild Chair Children's Hospital Los Angeles

Image of Alan S. Wayne, MD
Is this your profile? Click to edit

Overview

Alan S. Wayne, MD serves as Chair of the Department of Pediatrics at the Keck School of Medicine of USC and Senior Vice President of Academic Affairs and Pediatrician-in-Chief at Children’s Hospital Los Angeles (CHLA). Dr. Wayne is Professor of Pediatrics and Medicine at the Keck School of Medicine of USC. In these roles, Dr. Wayne oversees the Department’s clinical care delivery, medical education, and research programs, and leads the departmental strategy, faculty affairs, and budget management in the context of the missions of USC and CHLA.

Dr. Wayne’s primary research efforts are directed toward the development of new treatment approaches for leukemias and lymphomas, with a focus on targeted, immune-based, and cellular therapies. He is the Medical Director of the Therapeutic Advances in Childhood Leukemia/Lymphoma (TACL) Consortium, a multinational clinical trials group headquartered at CHLA. He has an ongoing leadership role in the development of genetically modified chimeric antigen receptor (CAR) T-cells for childhood hematologic malignancies. Additionally, he plays a leadership role in international efforts in the area of post-transplant relapse of hematologic malignancies, the primary aim of which is to study the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation.

Board-certified in pediatric hematology-oncology, Dr. Wayne attended the Honors Program in Medical Education obtaining his BS and MD degrees from Northwestern University. He conducted internship, residency, and chief residency in pediatrics at Boston Children’s Hospital followed by pediatric hematology-oncology fellowship at Boston Children’s Hospital and the Dana-Farber Cancer Institute.

Research Funding

  • Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency
    NIH · U01AI126612 · Aug 24, 2017 – Jul 31, 2024 · Role: Principal Investigator
  • University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG)
    NIH · P30CA014089 · Apr 1, 1980 – Nov 30, 2026 · Role: Principal Investigator
  • Pediatric Graft-vs-Host Disease
    NIH · Z01BC010596 · Role: Principal Investigator
  • Pediatric Oncology Branch Clinical Care and Education
    NIH · Z01BC010764 · Role: Principal Investigator
  • Experimental Therapeutics of Pediatric Hematopoietic Malignancies
    NIH · Z01SC010353 · Role: Principal Investigator
  • Pediatric Graft-vs-Host Disease
    NIH · ZICBC010596 · Role: Principal Investigator
  • Behavioral Science Core
    NIH · ZICBC011288 · Role: Principal Investigator
  • Experimental Therapeutics of Pediatric Hematopoietic Malignancies
    NIH · ZICSC010353 · Role: Principal Investigator
  • Pediatric Oncology Branch Clinical Care and Education
    NIH · ZIEBC010764 · Role: Principal Investigator

Publications

  • A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. Blood. 2021 02 18; 137(7):983-993.. View in PubMed
  • Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction. Pediatr Blood Cancer. 2021 01; 68(1):e28574.. View in PubMed
  • Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia. Blood. 2020 07 09; 136(2):210-223.. View in PubMed
  • CAR T-cell product performance in haematological malignancies before and after marketing authorisation. Lancet Oncol. 2020 02; 21(2):e104-e116.. View in PubMed
  • Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: Opportunities for improvement. Pediatr Blood Cancer. 2020 04; 67(4):e28149.. View in PubMed
  • Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. Clin Cancer Res. 2020 05 15; 26(10):2297-2307.. View in PubMed
  • Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020 05; 67(5):e28112.. View in PubMed
  • Extracellular vesicles derived from natural killer cells use multiple cytotoxic proteins and killing mechanisms to target cancer cells. J Extracell Vesicles. 2019; 8(1):1588538.. View in PubMed
  • Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia. Pediatr Blood Cancer. 2018 09; 65(9):e27265.. View in PubMed
  • Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia. Toxins (Basel). 2018 05 21; 10(5).. View in PubMed